CNTB
insider transactionsConnect Biopharma Holdings Ltd — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 90d
+1.3M
1.3M buy · 0 sell
Net value · 90d
$4.4M
$4.4M in · $0 out
Sentiment · 90d
Net buying
100% buying · 0% selling
Open-market trades · 90d
2
1.3M buy · 0 sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Buy·P
Director
$371.6K
150.0K sh · $2.48
Own +1%
-
Buy·P
Director
$4.0M
1.2M sh · $3.45
Own +10%
-
Grant·A
Kleanthis Gabriel Xanthopoulos
Director
$0
2.8K sh
Own +4%
-
Grant·A
Director
$0
5.1K sh
Own New
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| May 29, 2026 | James Huang | Buy P | 150.0K | $371.6K |
| Mar 31, 2026 | James Huang | Buy P | 1.2M | $4.0M |
| Mar 31, 2026 | Kleanthis Gabriel Xanthopoulos | Grant A | 2.8K | $0 |
| Mar 31, 2026 | Jean I Liu | Grant A | 5.1K | $0 |
About CNTB insider trading
This page tracks insider transactions for Connect Biopharma Holdings Ltd (CNTB) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.